Stockreport

DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 Conference [Yahoo! Finance]

Aptorum Group Limited - Class A Ordinary Shares  (APM) 
PDF of innovative blood-based diagnostic tests for brain health and other diseases, and Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage [Read more]